Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Stroke Patients Less Likely To Meet Treatment Goals Than Heart Disease Patients
A majority of high-risk stroke patients are less likely to meet clinical treatment targets to prevent repeat stroke or heart attacks compared to those with heart disease, suggesting the need to examine new therapeutic strategies, according to a study led by St. Michael"s Hospital neurologist Dr. Gustavo Saposnik. What"s more, medical procedures or ongoing specialty care may improve patients" awareness and consequent treatment success.
generic viagra online
When Young Men Are Scarce, They're More Likely To Play The Field Than To Propose
In places where young women outnumber young men, research shows the hemlines rise but the marriage rates don"t because the young men feel less pressure to settle down as more women compete for their affections.
News of the day
Putting A Name To A Face May Be Key To Brain's Facial Expertise
Our tendency to see people and faces as individuals may explain why we are such experts at recognizing them, new research indicates. This approach can be learned and applied to other objects as well.
Public Health

Results And Additional Analyses From Efficacy And Safety Study Of Corthera's Relaxin In Acute Heart Failure To Be Presented At Heart Failure Congress

Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Corthera"s investigational drug relaxin for the treatment of acute heart failure will be presented at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology in Nice, France. Marco Metra, M.D., professor of cardiology at the University of Brescia, Italy, and co-principal investigator of the Pre-RELAX-AHF study, will present the main results from the multicenter, international Pre-RELAX-AHF study at 8:30 a.m. CET on Sunday, May 31, at the Judges" Choice oral abstracts session. Dr. Metra will also present additional analyses of the Pre-RELAX-AHF study during a late-breaking clinical trials session at 11:15 a.m. CET on Monday, June 1. Five posters from the Pre-RELAX-AHF study will also be presented from 8:30 a.m. to 12:30 p.m. CET on Monday, June 1. About Relaxin Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women, including patients with heart failure. About Corthera Corthera Inc. is a private biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera"s lead product candidate, relaxin, is currently being evaluated in clinical trials for acute heart failure. The company has worldwide rights to develop and commercialize relaxin. Corthera Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009